Literature DB >> 27190020

Microvascular alterations and the role of complement in dermatomyositis.

Rajat Lahoria1, Duygu Selcen2, Andrew G Engel1.   

Abstract

Different mechanisms have been proposed to explain the pathological basis of perifascicular muscle fibre atrophy in dermatomyositis. These include ischaemia due to immune-mediated microvascular injury, enhanced expression of type 1 interferon-induced gene transcripts in perifascicular capillaries and muscle fibres, and occlusion of larger perimysial blood vessels. Microvascular complement deposition is a feature of dermatomyositis pathology but the trigger for complement activation, the predominant complement pathway involved, or its role in the pathogenesis of the disease, has not been clearly defined. In the first step of this study we examined the density of capillaries and transverse vessels and searched for occlusion or depletion of larger perimysial blood vessels in 10 patients with dermatomyositis. This revealed an invariable association of perifascicular atrophy with capillary and transverse vessel depletion. The capillary and transverse vessel densities in non-atrophic fibre regions were not significantly different from those in muscle specimens of 10 age-matched controls. Next, in the same 10, as well as in 40 additional dermatomyositis patients, we searched for vascular deposits of IgG, IgM, and the C5b-9 complement membrane attack complex. Thirty-one of 50 dermatomyositis specimens contained C5b-9 reactive endomysial microvessels but none of these or other vessels reacted for IgG. Ten of 50 specimens harboured IgM-positive capillaries but only a few of these reacted for C5b-9. Finally, we analysed and compared different pathways of complement activation in dermatomyositis, lupus nephritis, and necrotic muscle fibres in Duchenne dystrophy. In lupus nephritis, C5-b9 deposits co-localized with IgG, IgM, C1q, and C4d, consistent with immune complex dependent activation of the classical complement pathway. In both dermatomyositis and Duchenne dystrophy, C5-b9 deposits co-localized with C1q and C4d and rarely with IgM indicating activation of the classical complement pathway. We conclude that: perifascicular atrophy in dermatomyositis is consistently associated with focal microvascular depletion, and that microvascular membrane attack complex deposits in dermatomyositis result from activation of the classical complement pathway triggered by direct binding of C1q to injured endothelial cells.
© The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  complement activation; dermatomyositis; muscle microvasculature; perifascicular atrophy

Mesh:

Substances:

Year:  2016        PMID: 27190020     DOI: 10.1093/brain/aww122

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  19 in total

1.  Vascular changes and perifascicular muscle fiber damage in dermatomyositis: another question of the chicken or the egg that is on our mind.

Authors:  Boel De Paepe
Journal:  Ann Transl Med       Date:  2017-01

2.  Anti-aminoacyl-tRNA synthetase-related myositis and dermatomyositis: clues for differential diagnosis on muscle biopsy.

Authors:  Bruna Cerbelli; Annalinda Pisano; Serena Colafrancesco; Maria Gemma Pignataro; Marco Biffoni; Silvia Berni; Antonia De Luca; Valeria Riccieri; Roberta Priori; Guido Valesini; Giulia d'Amati; Carla Giordano
Journal:  Virchows Arch       Date:  2017-11-16       Impact factor: 4.064

3.  Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics.

Authors:  Rie Karasawa; Mayumi Tamaki; Toshiko Sato; Megumi Tanaka; Makiko Nawa; Kazuo Yudoh; James N Jarvis
Journal:  Rheumatology (Oxford)       Date:  2018-04-01       Impact factor: 7.580

Review 4.  Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity.

Authors:  Lauren M Pachman; Amer M Khojah
Journal:  J Pediatr       Date:  2018-04       Impact factor: 4.406

5.  Association of anti-HSC70 autoantibodies with cutaneous ulceration and severe disease in juvenile dermatomyositis.

Authors:  Rie Karasawa; Kazuo Yudoh; Toshiko Sato; Megumi Tanaka; Mayumi Tamaki; Sara E Sabbagh; Terrance P O'Hanlon; Payam Noroozi-Farhadi; Ira N Targoff; Willy A Flegel; Andrew L Mammen; Frederick W Miller; Mark D Hicar; Lisa G Rider; James N Jarvis
Journal:  Rheumatology (Oxford)       Date:  2022-07-06       Impact factor: 7.046

6.  Complement 7 Is Up-Regulated in Human Early Diabetic Kidney Disease.

Authors:  Monica Sircar; Ivy A Rosales; Martin K Selig; Dihua Xu; Zsuzsanna K Zsengeller; Isaac E Stillman; Towia A Libermann; S Ananth Karumanchi; Ravi I Thadhani
Journal:  Am J Pathol       Date:  2018-10       Impact factor: 4.307

7.  Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology.

Authors:  Elise Siegert; Akinori Uruha; Carsten Dittmayer; Werner Stenzel; Hans-Hilmar Goebel; Corinna Preuße; Vincent Casteleyn; Felix Kleefeld; Rieke Alten; Gerd R Burmester; Udo Schneider; Jakob Höppner; Kathrin Hahn
Journal:  Acta Neuropathol       Date:  2021-04-17       Impact factor: 17.088

Review 8.  Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options.

Authors:  Rachel Zeng; Stefanie Glaubitz; Jens Schmidt
Journal:  Neurotherapeutics       Date:  2022-04-08       Impact factor: 6.088

9.  Complement C7 is Specifically Expressed in Mesangial Cells and is a Potential Diagnostic Biomarker for Diabetic Nephropathy and is Regulated by miR-494-3p and miR-574-5p.

Authors:  Hang Guo; Zhiyue Yan; Yonghui Hu; Xitong Huang; Congqing Pan
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-05       Impact factor: 3.168

10.  Anasarca as the presenting symptom of juvenile dermatomyositis: a case series.

Authors:  Emily E Schildt; Deirdre De Ranieri
Journal:  Pediatr Rheumatol Online J       Date:  2021-08-13       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.